[1]
Darras B.T., Chiriboga C.A., Iannaccone S.T., et al.: Nusinersen in lateronset
spinal muscular atrophy: Long-term results from the phase 1/2
studies. Neurology 2019; 92: 2492–2506.
[2]
Gierlak-Wójcicka Z., Burlewicz M., Potulska-Chromik A., et al.: Przegląd
metod oceny funkcjonalnej u niesiedzących pacjentów z rdzeniowym
zanikiem mięśni (SMA). Neurol Dziec 2018; 54: 11–17.
[3]
Kroczka S., Steczkowska M., Kaciński M.: Neurophysiological studies
on muscles and peripheral nerves in children with moleculary diagnosed
spinal muscular atrophy, Child Neurology 2009; 35: 27–34.
[4]
Finkel R.S., Mercuri E., Darras B.T., et al.: Nusinersen versus Sham
Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med.
2017; 2: 377(18): 1723–1732.
[5]
Mandell J.R., Al-Zaidy S., Shell R., et al.: Single-Dose Gene-Replacement
Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017; 2: 377(18):
1713–1722.
[6]
Calucho M., Bernal S., March F., et al.: Correlation between SMA type
and SMN2 copy number revised: An analysis of 625 unrelated Spanish
patients and a compilation of 2834 cases. Neuromuscul Disord 2018; 28:
208–215.
[7]
Faravelli I., Meneri M., Saccomanno D., et al.: Nusinersen treatment
and cerebrospinal fluid neurofilaments: An explorative study on Spinal
Muscular Atrophy type 3 patients. J Cell Mol Med. 2020.
[8]
Goodkey K., Aslesh T., Maruyama R., et al.: Nusinersen in the Treatment
of Spinal Muscular Atrophy. Methods Mol Biol. 2018; 1828: 69–76.
[9]
Jędrzejowska M., Kostera-Pruszczyk A.: Rdzeniowy zanik mięśni – nowe
terapie, nowe wyzwania. Neurol Dziec 2016; 25, 51: 11–17.
[10]
Aragon-Gawińska K., Daron A., Ulinici A., et al.: Sitting in patients with
spinal muscular atrophy type 1 treated with nusinersen. Dev Med Child
Neurol. 2020; 62: 310–314.
[11]
Ramsey D., Scoto M., Mayhew A., et al.: Revised Hammersmith Scale
for spinal muscular atrophy: a SMA specific clinical outcome assessment
tool; PLoS One; 2017; 12: 2.
[12]
Krosschell K.J., Maczulski J.A., Crawford T.O., et al.: A modified
Hammersmith functional motor scale for use in multi- center research on
spinal muscular atrophy. Neuromuscul Disord. 2006; 16: 417–426.
[13]
Bérard C., Payan C., Hodgkinson I., et al.: MFM Collaborative Study Group.
A motor function measure for neuromuscular diseases. Construction and
validation study. Neuromuscul Disord 2005; 15: 463–470.
[14]
Montes J., Dunaway Young S., Mazzone E.S., et al.: Nusinersen improves
walking distance and reduces fatique in later-onset spinal muscular
atrophy. Muscle Nerve 2019; 60: 409–414.
[15]
Mazzone E.S., Mayhew A., Montes J., et al.: Revised upper limb module
for spinal muscular atrophy: Development of a new module. Muscle
Nerve 2016; 55: 869–874.